OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis
Events
You confirm that you have read our privacy policy. You can unsubscribe at any time by using the unsubscribe links.
